#Canada #Montreal #ExCellThera #UM171 #Zemcelpro®

ExCellThera and Medexus Team Up for Zemcelpro® in Canada

ExCellThera Inc., a leading innovator in blood stem cell technologies, has announced a significant partnership with Medexus that will potentially bring their advanced therapy, Zemcelpro® (dorocubicel), to the Canadian market. This exclusive licensing and supply agreement comes at a pivotal time as the drug has recently received conditional marketing authorization from the European Commission for treating hematological malignancies.

Details of the Partnership

The agreement allows Medexus to commercialize Zemcelpro® in Canada, pending approval from Health Canada. This innovative therapy focuses on personalized cryopreserved hematopoietic stem cell transplantation and comprises both UM171-expanded CD34+ cells and unexpanded CD34- cells, all sourced from the same cord blood unit. The anticipated timeline for commercialization in Canada is set for 2028, depending on regulatory pathways.

David Millette, CEO of Cordex Biologics, a subsidiary of ExCellThera, remarked on the significance of this partnership, expressing confidence that it will improve access to cutting-edge treatments for patients suffering from high-risk blood cancers who urgently need new therapeutic options. “These agreements with Medexus represent a vital milestone,” Millette stated, highlighting the shared goal to enhance patient care through innovative methods.

The Potential of Zemcelpro®

Zemcelpro® is poised to play a crucial role in addressing unmet medical needs in the realm of hematological cancers, specifically targeting conditions such as leukemias and myelodysplasias. Currently, Medexus is preparing to request Health Canada’s approval for the brand name Zemcelpro® as part of the necessary regulatory process.

The partnership not only creates commercial opportunities but also symbolically underscores Cordex's broader efforts to target international markets. With numerous global partnerships in the pipeline, Cordex aims to expedite the availability of Zemcelpro® across Europe and beyond.

As a reputable company within hematology and oncology, Medexus brings invaluable expertise to this joint venture. The agreement will feature provisions for royalties based on Canadian sales and milestone payments, reflecting a mutual interest in the commercial success of Zemcelpro®.

A Bright Future for Innovative Therapies

Zemcelpro® has been tested across multiple clinical trials with over 120 patients afflicted with hematologic malignancies in North America and Europe. Importantly, it has earned various designations from regulatory bodies, underscoring its potential as a transformative treatment method in stem cell transplantation. This therapy represents a beacon of hope for those battling aggressive blood cancers, particularly patients with limited treatment options, such as those with TP53 mutations or requiring additional transplants.

The journey ahead may include expanding the therapy's use to pediatric patients and individuals suffering from non-malignant hematological disorders, depending on safety and efficacy findings from ongoing investigations.

With robust trial outcomes and an innovative approach, Zemcelpro® stands out as a revolutionary advancement in cancer treatment. As ExCellThera and Medexus press forward, their commitment to developing groundbreaking therapies promises to bring long-lasting benefits to patients who need it most.

For more information on ExCellThera and their advancements in stem cell therapy, please visit ExCellThera’s website.